Biogen (BIIB) Stock Forecast & Price Target

$120.57 +0.40 (+0.33%)

As of 02:51 PM Eastern

Biogen - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 32 Analyst Ratings

Sell
0

Hold
20

Buy
12

Based on 32 Wall Street analysts who have issued ratings for Biogen in the last 12 months, the stock has a consensus rating of "Hold." Out of the 32 analysts, 20 have given a hold rating, and 12 have given a buy rating for BIIB.

Consensus Price Target

$201.93
67.48% Upside

According to the 32 analysts' twelve-month price targets for Biogen, the average price target is $201.93. The highest price target for BIIB is $300.00, while the lowest price target for BIIB is $115.00. The average price target represents a forecasted upside of 67.48% from the current price of $120.57.

Get the Latest News and Ratings for BIIB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Biogen and its competitors.

BIIB Analyst Ratings Over Time

Type	Current Forecast 4/30/24 to 4/30/25	1 Month Ago 3/31/24 to 3/31/25	3 Months Ago 1/31/24 to 1/30/25	1 Year Ago 5/1/23 to 4/30/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)	18 Buy rating(s)
Hold	20 Hold rating(s)	17 Hold rating(s)	16 Hold rating(s)	9 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$201.93	$213.33	$228.80	$293.88
Forecasted Upside	67.48% Upside	55.90% Upside	56.47% Upside	36.81% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

BIIB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BIIB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biogen Stock vs. The Competition

Type	Biogen	Medical Companies	S&P 500
Consensus Rating Score	2.38	2.82	2.54
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	68.03% Upside	3,089.28% Upside	20.03% Upside
News Sentiment Rating	Positive News See Recent BIIB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/29/2025	Truist Financial 2 of 5 stars	Srikripa Devarakonda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$210.00 ➝ $199.00	+64.66%
4/29/2025	Piper Sandler 2 of 5 stars	Christopher Raymond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$135.00 ➝ $115.00	-4.48%
4/28/2025	HSBC 2 of 5 stars		Downgrade	Buy ➝ Hold	$118.00	-0.71%
4/28/2025	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Herholdt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/25/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Fadia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/23/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$219.00 ➝ $197.00	+63.72%
4/22/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$221.00 ➝ $225.00	+91.28%
4/9/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$157.00 ➝ $152.00	+36.93%
4/4/2025	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jasper Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
2/13/2025	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	George Farmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sector Outperform ➝ Sector Outperform	$244.00 ➝ $224.00	+61.69%
Get the Latest News and Ratings for BIIB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.
2/13/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Seigerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Perform ➝ Market Perform	$156.00 ➝ $139.00	+1.30%
2/13/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Meacham Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$160.00 ➝ $145.00	+6.96%
2/13/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$165.00 ➝ $140.00	+4.40%
2/13/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Fein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$300.00 ➝ $241.00	+80.62%
2/13/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Sumant Kulkarni Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$298.00 ➝ $265.00	+98.61%
2/11/2025	Bank Of America (Bofa) Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$178.00 ➝ $163.00	+16.94%
2/11/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Gal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$160.00	+12.25%
1/13/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
12/16/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$175.00	+16.64%
12/10/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral	$178.00	+13.77%
12/9/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$250.00 ➝ $180.00	+14.08%
11/21/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$251.00 ➝ $207.00	+32.69%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
11/15/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$294.00 ➝ $300.00	+81.94%
11/4/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$220.00 ➝ $210.00	+22.40%
10/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$190.00 ➝ $180.00	+2.18%
10/31/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$270.00 ➝ $255.00	+44.75%
10/31/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$300.00 ➝ $275.00	+56.24%
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/3/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Verma Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$234.00 ➝ $202.00	+9.42%
9/23/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$210.00 ➝ $205.00	+4.17%
9/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$292.00 ➝ $292.00	+46.34%
1/7/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Shrader Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
8/8/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$282.00 ➝ $275.00	+1.39%
5/1/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$270.00 ➝ $350.00	+15.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 02:58 PM ET.

Should I Buy Biogen Stock? BIIB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 29, 2025. Please send any questions or comments about these Biogen pros and cons to contact@marketbeat.com.

Biogen
Bull Case

Here are some ways that investors could benefit from investing in Biogen Inc.:

The current stock price is around $120, which may present a buying opportunity for investors looking for value in the biotechnology sector.
Recent institutional interest has been strong, with several hedge funds increasing their stakes in Biogen Inc., indicating confidence in the company's future performance.
Biogen Inc. has a solid market capitalization of approximately $17.57 billion, suggesting it is a well-established player in the biotechnology industry.
Analysts have mixed but generally positive ratings, with some firms maintaining "buy" ratings, which could indicate potential for stock appreciation.
The company has a relatively low P/E ratio of about 10.76, which may suggest that the stock is undervalued compared to its earnings, making it an attractive option for value investors.

Biogen
Bear Case

Investors should be bearish about investing in Biogen Inc. for these reasons:

Piper Sandler recently reduced its price target for Biogen Inc. from $135 to $115, indicating a potential downside and reflecting concerns about the company's growth prospects.
There has been a significant decrease in insider ownership, with a director selling a substantial number of shares, which could signal a lack of confidence in the company's future performance.
Biogen Inc. has experienced volatility in its stock price, with a twelve-month high of $238 and a low of $110, suggesting uncertainty in its market position.
Recent reports indicate that the consensus rating for Biogen Inc. is "Hold," which may imply that analysts are not overly optimistic about immediate growth.
The company has a relatively high debt-to-equity ratio of 0.27, which could indicate financial risk if the company faces challenges in generating revenue.

BIIB Forecast - Frequently Asked Questions

: According to the research reports of 32 Wall Street equities research analysts, the average twelve-month stock price forecast for Biogen is $201.93, with a high forecast of $300.00 and a low forecast of $115.00.
: 32 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 20 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BIIB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIIB, but not buy additional shares or sell existing shares.
: According to analysts, Biogen's stock has a predicted upside of 67.48% based on their 12-month stock forecasts.
: Over the previous 90 days, Biogen's stock had 3 downgrades by analysts.
: Biogen has been rated by research analysts at Argus, Bank Of America (Bofa), BMO Capital Markets, Canaccord Genuity Group, Citigroup, HC Wainwright, Hsbc Global Res, HSBC, Morgan Stanley, Needham & Company LLC, Piper Sandler, Royal Bank of Canada, Sanford C. Bernstein, Scotiabank, The Goldman Sachs Group, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Biogen less than other "medical" companies. The consensus rating for Biogen is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BIIB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:BIIB) was last updated on 4/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biogen (BIIB) Stock Forecast & Price Target